Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444263 | 0.89 | MEN1 (0.31) | MEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL20008986 | 0.80 | SMN1; SMN2 (0.37) | GRM5SMN1; SMN2HRH3CYP2D6KCNH2 | |
| SCHEMBL21722669 | 0.80 | HRH3 (0.33) | HRH3CYP2D6KCNH2MAPT | |
| SCHEMBL18375130 | 0.80 | SMN1; SMN2 (0.37) | GRM5SMN1; SMN2HRH3CYP2D6KCNH2 | |
| SCHEMBL7839622 | 0.79 | TLR9 (0.32) | HSD17B10HRH3CYP2D6KCNH2MAPT | |
| SCHEMBL15196701 | 0.78 | ALDH1A1 (0.42) | HRH3CYP2D6KCNH2 | |
| SCHEMBL26203667 | 0.77 | ALDH1A1 (0.32) | HRH3CYP2D6KCNH2 | |
| SCHEMBL7851975 | 0.77 | HRH3 (0.41) | HRH3GAAMAPT | |
| SCHEMBL20682344 | 0.76 | TSHR (0.38) | GRM5KCNH2MAPT | |
| SCHEMBL20009056 | 0.76 | HRH3 (0.37) | HRH3CYP2D6KCNH2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | GRM5 1607/4885MEN1 1824/4885KMT2A 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.